Literature DB >> 12127425

Leptin is essential for the hepatic fibrogenic response to chronic liver injury.

Isabelle A Leclercq1, Geoffrey C Farrell, Rixt Schriemer, Graham R Robertson.   

Abstract

BACKGROUND/AIMS: Obesity is associated with hyperleptinemia and is also a risk factor for fibrosis and severity of fibrosis in several chronic liver diseases. The correlation between increased leptin, obesity and hepatic fibrosis prompted us to hypothesise that leptin has profibrogenic effects on the liver.
METHODS: We analysed the role of leptin in liver fibrosis in leptin-deficient mice fed a diet which generates steatohepatitis, and in chronic carbon tetrachloride-induced hepatic injury.
RESULTS: Leptin-deficient mice failed to develop fibrosis during steatohepatitis or in response to chronic toxic liver injury, and failed to up-regulate collagen-I while developing similar hepatic injury as their genetic controls. Restitution of physiological levels of circulating leptin by injection of exogenous leptin, but not correction of the obese phenotype by dietary manipulation, restored liver fibrosis in leptin-deficient mice during chronic liver injury. These results confirmed the absolute requirement of leptin for hepatic fibrosis. We showed that leptin deficiency did not alter hepatic TNF regulation but that leptin is necessary for induction of bioactive transforming growth factor beta 1 (TGFbeta1) protein in the context of chronic liver injury.
CONCLUSIONS: These data establish that leptin is an essential mediator of hepatic fibrosis in response to chronic liver injury, whether metabolic or toxic in aetiology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127425     DOI: 10.1016/s0168-8278(02)00102-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  103 in total

1.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 2.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

Review 3.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A M Diehl; Z P Li; H Z Lin; S Q Yang
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

4.  Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism.

Authors:  Songbai Lin; Neeraj K Saxena; Xiaokun Ding; Lance L Stein; Frank A Anania
Journal:  Mol Endocrinol       Date:  2006-08-24

Review 5.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

Review 6.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

7.  Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase.

Authors:  Youcai Tang; Anping Chen
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling.

Authors:  Youcai Tang; Shizhong Zheng; Anping Chen
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

Review 9.  Treatment of hepatic fibrosis: almost there.

Authors:  Efsevia Albanis; Rifaat Safadi; Scott L Friedman
Journal:  Curr Gastroenterol Rep       Date:  2003-02

10.  Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice.

Authors:  Xiaobing Tan; Xiuhua Sun; Qiong Li; Yantao Zhao; Wei Zhong; Xinguo Sun; Wei Jia; Craig J McClain; Zhanxiang Zhou
Journal:  Am J Pathol       Date:  2012-07-27       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.